Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Biol Pharm Bull ; 44(5): 653-658, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33952821

RESUMO

Alogliptin (ALG), an inhibitor of dipeptidylpeptidase-4, is used in the management of type 2 diabetes mellitus, and has a high absorption rate (>60-71%), despite its low lipophilicity (logP=-1.4). Here, we aimed to clarify the mechanism of its intestinal absorption. ALG uptake into Caco-2 cells was time-, temperature-, and concentration-dependent, but was not saturated at concentrations up to 10 mmol/L. The uptake was significantly inhibited by the organic anion transporting polypeptide (OATP) substrate fexofenadine and by the OATP inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), but was not inhibited by organic cation transporter (OCT)/organic cation/carnitine transporter (OCTN) or peptide transporter 1 (PEPT1) substrates. Grapefruit, orange, and apple juices and their constituents, which are known to strongly inhibit intestinal OATPs, significantly inhibited ALG uptake into Caco-2 cells. The pH dependence was bell-shaped, indicating the involvement of a pH-sensitive transporter. However, ALG uptake by HEK293 cells overexpressing OATP2B1, a key intestinal OATP transporter of amphiphilic drugs, was not different from that of mock cells. In a rat in vivo study, apple juice reduced systemic exposure to orally administered ALG without changing the terminal half-life. These observations suggest that intestinal absorption of ALG is carrier-mediated, and involves a fruit-juice-sensitive transporter other than OATP2B1.


Assuntos
Interações Alimento-Droga , Sucos de Frutas e Vegetais , Transportadores de Ânions Orgânicos/metabolismo , Piperidinas/farmacocinética , Uracila/análogos & derivados , Ácido 4,4'-Di-Isotiocianoestilbeno-2,2'-Dissulfônico/farmacologia , Administração Oral , Animais , Células CACO-2 , Citrus paradisi , Citrus sinensis , Diabetes Mellitus Tipo 2/tratamento farmacológico , Células HEK293 , Meia-Vida , Humanos , Absorção Intestinal , Masculino , Malus , Transportadores de Ânions Orgânicos/antagonistas & inibidores , Piperidinas/administração & dosagem , Ratos , Terfenadina/análogos & derivados , Terfenadina/farmacologia , Uracila/administração & dosagem , Uracila/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA